# Sphera Global Healthcare Fund

> Sphera Global Healthcare Fund is a VC fund backing Biotechnology. See 30 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Tel Aviv, Israel
- Total investments: 30
- Last investment: Aug 2026
- Lead investor: 7%
- Last updated: Sep 2026
- Website: http://www.spherafund.com/sphera_global_healthcare_fund.html

Sphera Global Healthcare Fund is a VC fund in Tel Aviv focused on Biotechnology and Pharmaceutical. Sphera Global Healthcare Management (Investment Manager) is a partnership between Mr. Mori Arkin, former vice chairman of Perrigo (Nasdaq ticker:PRGO, a world leader in generic and OTC drugs), and of Sphera Funds Management.It is a long/short equity fund that is focused on the global pharmaceutical and biotech industries. The InvestmentManager’s objective is to generate consistent and attractive long term returns exceeding the industry while maintaining disciplined risk management. With a highly experienced and cohesive multidisciplinary team, the Fund’s competitive advantage is evident in three key areas:• Having a rigorous, fundamental, focused and comprehensive approach to healthcare research.• Investment committee co- led by an industry veteran with a track record of building a pharmaceutical company.• Unique and unbiased investment approach generated in part from access to massive flow of R &D, innovation and top tier human capital in Israel.

## Contacts

5 contacts available for Sphera Global Healthcare Fund. Shizune tracks 7 team members at Sphera Global Healthcare Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sphera-global-health-care-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 28 | 93% |
| Pharmaceutical | 16 | 53% |
| Health Care | 13 | 43% |
| Therapeutics | 13 | 43% |
| Medical | 9 | 30% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 20 | 67% |
| Series B | 3 | 10% |
| Series C | 2 | 7% |
| Series E | 2 | 7% |
| Series A | 1 | 3% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 50% |
| Canada | 5 | 17% |
| China | 2 | 7% |
| Sweden | 2 | 7% |
| France | 1 | 3% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Amit Drach | Senior Scientific Analyst | 0 | — |
| Doron Breen | Partner and Fund Manager | 0 | — |
| Geula Schwartz | Analyst | 0 | — |
| Hagai Schor | Head of Scientific Research | 0 | — |
| Joon Lee | Analyst | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quoin Pharmaceuticals | Quoin Pharmaceuticals is into developing products which address major unmet medical needs including the opioid epidemic and the military veteran suicide rate and chronic rare skin diseases such as Netherton syndrome and Dystrophic Epidermolysis Bullosa (DEB). | $50M | Post-IPO Equity | Aug 28, 2026 |  |
| Werewolf Therapeutics | Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $150M | Post-IPO Equity | Aug 21, 2026 |  |
| Sensorion | Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $71.5M | Post-IPO Equity | Jan 28, 2026 |  |
| Eledon Pharmaceuticals | Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. | $85M | Post-IPO Equity | Oct 29, 2024 |  |
| enGene | enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expressionlevels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes. | $43.2M | Post-IPO Equity | Oct 25, 2024 |  |
| ProMIS Neurosciences | ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).It was founded in 2004 and headquartered in Toronto,Canada. | $30.3M | Post-IPO Equity | Jul 26, 2024 |  |
| Chemomab | Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and blockCCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022. | $10M | Post-IPO Equity | Jul 25, 2024 |  |
| Hansa Biopharma | Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic ordisease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications. | $34.2M | Post-IPO Equity | Apr 12, 2024 |  |
| Helus Pharma | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $150M | Post-IPO Equity | Mar 13, 2024 |  |
| Aprea | Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicleowned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB. | $16M | Post-IPO Equity | Mar 11, 2024 |  |

10 of 30 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 9 deals together
- [Woodline Partners](https://shizune.co/investors/profile/woodline-partners) — VC Fund, 6 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 5 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 5 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 5 deals together
- [Altium Capital](https://shizune.co/investors/profile/altium-capital) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Sphera Global Healthcare Fund invest in?

Sphera Global Healthcare Fund invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Post-IPO Equity and Series B stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sphera Global Healthcare Fund?

Public channels for Sphera Global Healthcare Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sphera Global Healthcare Fund?

The team at Sphera Global Healthcare Fund includes Amit Drach (Senior Scientific Analyst), Doron Breen (Partner and Fund Manager) and Geula Schwartz (Analyst), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co